Imagine a future in which cancer screening could be done through a simple urine analysis. The test could be offered at your doctor’s office and would require no fasting or preparation beforehand. What’s more, it could increase accessibility for people living in remote or rural areas and save thousands of lives in the developing world.
Thanks to DynaLIFE Medical Lab’s local health accelerator space in downtown Edmonton, that future might not be too far off.
Today, the accelerator is home to five medical startups looking to bring their discoveries to market. Often, these innovations come out of research performed at the University of Alberta and University of Calgary, and through the health accelerator, they’re able to tap into DynaLIFE’s industry knowledge and supports to scale up and commercialize their technologies.
“Our goal is to use our expertise, scale and scope to make these technologies accessible to Albertans, while encouraging these companies, their talent and their researchers to stay in Alberta,” says Jason Pincock, chief executive officer for DynaLIFE. “If we’re able to do that, and create an environment that they will stay in and create their second, third and fourth products here, we can build jobs, companies and a stronger industry here in Edmonton.”
In the past, the path from research to market has been challenging for many Edmonton-based researchers and innovators. With few or no local success stories to partner with or learn from, many have been left with no choice but to sell their discoveries to a company better equipped to navigate the commercialization process.
“So how do we change that?” says Pincock. “We build the accelerator and make business happen here.”
Today, Nanostics and Metalobomic Technologies Inc. (MTI) are two of the first startups to capitalize on the DynaLIFE accelerator space. Both companies are focused on creating less-invasive cancer screening technologies; Nanostics uses machine learning and artificial intelligence to improve prostate cancer screening, while MTI has developed a urine test to detect adenomatous polyps, the precursor to colorectal cancer.